ヘマトクリット検査機器市場：製品・用途・エンドユーザー・地域別、2026～2032年

ヘマトクリット検査機器市場の評価-2026～2032年

自動分析機器や携帯型ポイントオブケアツールなどの開発は、より迅速、正確、便利な検査を提供することで市場成長を促進します。このように、技術的進歩は、市場規模の成長を急増させ、2024年には43億6,000万米ドルを超え、2032年には57億8,000万米ドルの評価額に達します。

ヘルスケア支出の増加は、診断ツールへの投資拡大を支え、ヘマトクリット検査機器の技術革新と採用を加速させています。したがって、ヘルスケア支出の増加により、市場は2026～2032年にかけてCAGR 3.60%で成長します。

ヘマトクリット検査機器市場定義/概要

ヘマトクリット検査機器は、診断医療において不可欠なツールであり、人の総血液量に占める赤血球（RBC）の割合を測定するために使用されます。ヘマトクリット値として知られるこの測定値は、発熱のような軽度の病気から貧血やがんのような重篤な病気に至るまで、様々な健康状態に関する貴重な洞察を記載しています。ヘマトクリット検査では、全血液量に対する赤血球量の比率を計算します。正常範囲からの逸脱は、赤血球の生産や寿命に影響する状態を示すことがよくあります。

ヘマトクリット検査を行うには、通常、指刺しまたは静脈穿刺で少量の血液サンプルを採取します。その後、サンプルを専用のチューブに入れ、遠心分離機で回転させます。これにより血液成分が密度によって分離され、赤血球がチューブの底に沈殿します。自動分析機器とポイントオブケア型ヘマトクリット検査機器がこのプロセスを進歩させ、より速く、より正確に、より便利にしました。これらの機器はデジタル技術との統合が進み、検査の効率と信頼性が向上しています。ヘマトクリット検査機器は、早期診断とモニタリングにおいて重要な役割を果たし、ヘルスケアプロバイダがさまざまな健康状態を管理し、患者の転帰を向上させるのをサポートします。

ヘマトクリット検査需要の増加がヘマトクリット検査機器市場の成長をどのように押し上げたか？

貧血、多血症、その他の血液疾患の症例が増加しており、早期診断と効果的な疾患管理のためにヘマトクリット検査の需要が増加しています。WHO（2022年）は、非伝染性疾患は毎年4,100万人の死亡を引き起こし、これは世界全体の死亡の74%に相当すると報告しています。CDC（2021年）は、1億3,300万人のアメリカ人が少なくとも1つの慢性疾患を抱えていると述べています。NIH（2022年）によると、糖尿病の有病率は2020年以降、世界で8.5％増加しました。増加する高齢者は貧血や様々な血液疾患に罹患しやすく、定期的なヘマトクリット検査は健康状態のモニタリングと合併症の予防に不可欠です。高齢者の増加に伴い、これらの検査や機器に対する需要は増加すると予想されます。国連の世界人口展望では、2022年の65歳以上の人口は2050年までに16億人に達します。WHOは、高齢者の80％が少なくとも1つの慢性疾患を抱えていると推定しています。欧州連合は、2020～2022年にかけて高齢者ケアのためのヘルスケア支出が15%増加すると報告。

米国赤十字社（2022年）は、米国では1日に約29,000個の赤血球が必要であると報告。WHOは、世界的に献血需要が6％増加すると報告。救急部門における輸血処置は18％増加。

自動分析機器や携帯型ポイントオブケア機器を含むヘマトクリット検査機器の進歩は、より迅速で正確かつ便利な検査ソリューションを提供することで市場の成長を促進しています。自動化とデジタル技術の統合は検査効率と信頼性をさらに高め、ヘルスケアにおけるこれらの機器の価値をますます高めています。FDAが2022年に承認したポイントオブケア機器は、2020年と比較して28%増加しています。NIHの報告によると、POC検査市場は2020～2023年にかけて12.3%のCAGRで成長しました。POC検査のメディケア請求は2020～2022年に34%増加。世界アンチ・ドーピング機構（2022年）：アスリートの血液検査が15％増加。オリンピック委員会（2021年）は、持久系スポーツの85％にヘマトクリットモニタリングの義務化を実施。スポーツ医療協会によると、スポーツ医療市場は2022年までに72億米ドルに達します。

高い検査コストはヘマトクリット検査機器市場の成長をどのように阻害するか？

ヘマトクリット検査は、他の診断手順とともに、特に発展途上国では費用がかかることがあります。このため、経済的に余裕のない人々の検査へのアクセスが制限され、アクセスを拡大するために、より手頃な価格の診断オプションの必要性が強調されています。NIH（2022年）によれば、医療機器の研究開発費は2020～2022年にかけて32％増加しました。FDAの報告によれば、新規診断機器の平均開発費は2022年に3,100万米ドルに達しました。医療技術協会（2021年）は、小規模医療機器企業の45%が研究開発コストの高さを成長の主要障壁として挙げていると指摘しています。

多くの地域、特に発展途上国では、ヘルスケア施設、診断ラボ、血液バンクへのアクセスが不十分です。このため、特に農村部や十分なサービスを受けていない地域では、ヘマトクリット検査サービスの利用が制限されています。WHO（2022年）は、世界人口の47％が必要不可欠な診断サービスを利用できていないと報告しています。世界銀行は、低所得国のヘルスケア施設の38％しか基本的な診断機器を備えていないと報告しています。ユニセフ（2023年）は、32億人が体外診断検査を受けられないと述べています。農村部や十分なサービスを受けていない地域の限られたヘルスケアインフラが、ヘマトクリット検査の利用を妨げています。この課題に対処し、より広範な検査の利用を支援するためには、ヘルスケアインフラを拡大し、診断サービスへのアクセスを改善する課題が不可欠です。

目次

第1章 ヘマトクリット検査機器の世界市場導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 ヘマトクリット検査機器の世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 ヘマトクリット検査機器の世界市場：製品別

• 概要
• ヘマトクリット検査メーター
• ヘマトクリット検査機器
• 試薬と消耗品

第6章 ヘマトクリット検査機器の世界市場：用途別

• 概要
• 貧血
• ベラ多血症
• 先天性心疾患
• その他

第7章 ヘマトクリット検査機器の世界市場：エンドユーザー別

• 概要
• 病院クリニック
• 診断センター
• その他

第8章 ヘマトクリット検査機器の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋
• その他
  • ラテンアメリカ
  • 中東・アフリカ

第9章 世界のヘマトクリット検査機器市場の競合情勢

• 概要
• 各社の市場ランキング
• 主要開発戦略

第10章 企業プロファイル

• Sysmex Corporation
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Siemens AG
• Beckman Coulter
• Nihon Kohden Corporation
• Boule Diagnosis AB
• EKF Diagnostics
• Nova Biomedical
• HORIBA Ltd.

第11章 付録

• 関連調査

Hematocrit Test Devices Market Valuation - 2026-2032

The development of advanced devices, including automated analyzers and portable point-of-care tools, enhances market growth by offering faster, more accurate, and convenient testing. Thus, the technological advancements surge the growth of market size surpassing USD 4.36 Billion in 2024 to reach the valuation of USD 5.78 Billion by 2032.

Rising healthcare expenditure supports greater investment in diagnostic tools, accelerating the innovation and adoption of hematocrit test devices. Thus, the increasing healthcare expenditure enables the market to grow at a CAGR of 3.60% from 2026 to 2032.

Hematocrit Test Devices Market: Definition/ Overview

Hematocrit test devices are essential tools in diagnostic medicine, used to measure the proportion of red blood cells (RBCs) in a person's total blood volume. This measurement, known as hematocrit, provides valuable insights into various health conditions, from mild ailments like fever to more serious diseases such as anemia or cancer. A hematocrit test calculates the ratio of RBC volume to total blood volume, with deviations from normal ranges often indicating conditions that affect red blood cell production or lifespan.

To perform a hematocrit test, a small blood sample is collected, usually through a finger prick or venipuncture. The sample is then placed in a specialized tube and spun in a centrifuge, which separates the blood components by density, allowing the red blood cells to settle at the bottom of the tube. Automated analyzers and point-of-care hematocrit test devices have advanced this process, making it faster, more accurate, and more convenient. These devices are increasingly integrated with digital technologies, improving the efficiency and reliability of testing. Hematocrit test devices play a crucial role in early diagnosis and monitoring, supporting healthcare providers in managing various health conditions and enhancing patient outcomes.

How the Increasing Demand for Hematocrit Testing Surge the Growth of Hematocrit Test Devices Market?

Growing cases of anemia, polycythemia, and other blood disorders are increasing the demand for hematocrit testing for early diagnosis and effective disease management. WHO (2022) reported that non-communicable diseases cause 41 million deaths each year, equivalent to 74% of all deaths globally. CDC (2021) stated that 133 million Americans have at least one chronic disease. According to NIH (2022), diabetes prevalence increased by 8.5% globally since 2020. The increasing geriatric population is more prone to anemia and various blood disorders, making regular hematocrit testing essential for monitoring health and preventing complications. With a growing elderly population, the demand for these tests and devices is expected to rise. UN World Population Prospects 2022 people aged 65+ will reach 1.6 billion by 2050. WHO estimated that 80% of older adults have at least one chronic condition. The European Union reported a 15% increase in healthcare spending for elderly care from 2020-2022.

American Red Cross (2022) nearly 29,000 units of red blood cells are needed daily in the U.S. WHO reported a 6% increase in blood donation demands globally. Blood transfusion procedures increased by 18% in emergency departments.

Advancements in hematocrit test devices, including automated analyzers and portable point-of-care units, are driving market growth by offering faster, more accurate, and convenient testing solutions. The integration of automation and digital technologies further enhances testing efficiency and reliability, making these devices increasingly valuable in healthcare. FDA approved 28% more point-of-care devices in 2022 compared to 2020. NIH reported that the POC testing market grew at 12.3% CAGR from 2020-2023. Medicare claims for POC testing increased by 34% between 2020-2022. World Anti-Doping Agency (2022): 15% increase in blood testing among athletes. The Olympic Committee (2021) implemented mandatory hematocrit monitoring for 85% of endurance sports. According to the Sports Medicine Association, the sports medicine market will reach $7.2 billion by 2022.

How does the High Testing Cost Impede the Growth of the Hematocrit Testing Device Market?

Hematocrit testing, along with other diagnostic procedures, can be costly, especially in developing countries. This limits access to testing for individuals with limited financial resources, highlighting the need for more affordable diagnostic options to broaden access. According to NIH (2022), medical device R&D costs increased by 32% from 2020-2022. FDA reported that the average development cost for new diagnostic devices reached USD 31 Million in 2022. Medical Technology Association (2021) noted that 45% of small device companies cited high R&D costs as their primary growth barrier

In many regions, particularly in developing countries, access to healthcare facilities, diagnostic laboratories, and blood banks is insufficient. This restricts the availability of hematocrit testing services, especially in rural and underserved areas. WHO (2022) reported that 47% of the global population lacks access to essential diagnostic services. World Bank only 38% of healthcare facilities in low-income countries have basic diagnostic equipment. UNICEF (2023) stated that 3.2 billion people lack access to in-vitro diagnostic testing. Limited healthcare infrastructure in rural and underserved areas hinders the accessibility of hematocrit testing. Efforts to expand healthcare infrastructure and improve diagnostic service access are essential to address this challenge and support broader testing availability.

Category-Wise Acumens

How the Compact and Portable Design Surge the Growth of Hematocrit Test Meter Segment?

The hematocrit test meter segment dominates the Hematocrit Test Devices Market, owing to its compact and portable design that makes it well-suited for point-of-care testing across diverse healthcare settings, including primary care, clinics, and home healthcare. These meters are user-friendly, highly transportable, and cost-effective, offering a practical solution for settings where access to larger, stationary equipment is limited. Their rapid result delivery enables healthcare providers to diagnose and treat conditions promptly, which is especially beneficial in urgent care scenarios.

To address the rising demand for point-of-care testing, manufacturers are prioritizing the development of smaller and even more portable hematocrit test meters, enhancing their usability in various environments. Additionally, the integration of these devices with digital health platforms facilitates remote monitoring and data analysis, allowing healthcare professionals to track patients' hematocrit levels and overall health remotely. Ongoing advancements in automation are further improving the functionality of hematocrit test meters, increasing their testing throughput and accuracy. This combination of portability, digital integration, and automation makes hematocrit test meters a key growth driver in the Hematocrit Test Devices Market, as they support efficient, accessible, and reliable diagnostics.

How does the Deficiency of Red Blood Cells and Monitoring for Effective Treatment Foster the Growth of the Anemia Segment?

The anemia segment is dominant in the Hematocrit Test Devices Market owing to the critical role of hematocrit testing in diagnosing and managing anemia. Anemia, characterized by a deficiency of red blood cells or hemoglobin, is a widespread condition requiring timely detection and ongoing monitoring for effective treatment. Hematocrit tests enable early identification of anemia, which is essential for initiating prompt treatment to prevent further health complications.

Monitoring hematocrit levels also allows healthcare providers to track the effectiveness of anemia treatments over time, ensuring that treatment plans are achieving the desired outcomes. Beyond anemia, hematocrit testing is expanding into applications like assessing hydration status, evaluating kidney function, and identifying nutritional deficiencies, broadening the utility of these devices. Additionally, the shift toward personalized medicine has further strengthened demand in the anemia segment. Hematocrit tests can support tailored treatment plans by offering insight into an individual's unique health needs, enabling clinicians to adjust treatments accordingly.

Country/Region-wise Acumens

How the Advanced Healthcare Infrastructure & High Healthcare Spending Hematocrit Test Devices Market in North America?

North America substantially dominates the Hematocrit Test Devices Market driven by the region's benefits from a robust healthcare infrastructure, featuring advanced diagnostic facilities and a highly skilled healthcare workforce. U.S. healthcare spending reached USD 4.3 Trillion in 2021. American Hospital Association (2022) reported 6,093 hospitals with advanced diagnostic facilities. Healthcare spending per capita in the U.S. increased by 9.7% from 2020-2022.

The increasing prevalence of chronic diseases such as diabetes, cardiovascular conditions, and kidney disorders drives the need for regular blood tests, including hematocrit testing, to support effective management and treatment. CDC (2022) reported that 6 in 10 U.S. adults have a chronic disease, with 4 in 10 having multiple conditions. American Cancer Society (2021) estimated 1.9 million new cancer cases, require regular blood monitoring. NIH (2023) data showed that anemia affects approximately 5.6% of the U.S. population, with higher rates in the elderly and women.

FDA approved 37% more hematology devices in 2022 compared to 2020. The U.S. medical device industry invested $22.4 billion in R&D. Clinical trials for hematology devices increased by 28% between 2020-2023.

How Economic Growth and Increasing Healthcare Investment Surge the Growth of Hematocrit Test Devices Market in Asia Pacific?

Asia Pacific is anticipated to witness the fastest growth in the Hematocrit Test Devices Market during the forecast period owing to the rapid economic growth in countries like China, India, and South Korea is leading to increased healthcare spending and improved healthcare infrastructure. China's healthcare spending grew by 12.8% to reach USD 1.1 Trillion in 2022 (National Bureau of Statistics of China). India increased its healthcare budget by 137% between 2020-2023. Southeast Asian healthcare infrastructure investments reached USD 28.5 Billion in 2022.

The increasing prevalence of chronic diseases, such as diabetes, cardiovascular diseases, and anemia is driving the demand for diagnostic tools like hematocrit test devices. WHO Western Pacific Region (2022) reported 1.9 billion people with 35% above the age of 50. China CDC (2021) documented 116 million diabetes cases requiring regular blood monitoring. Indian Council of Medical Research (2022) reported a 38% increase in blood disorder cases. Thailand welcomed 3.5 million medical tourists in 2022. Singapore's medical tourism revenue grew by 15% annually from 2020-2022. South Korea reported a 25% increase in international patients for medical procedures.

Competitive Landscape

The Hematocrit Test Devices Market is characterized by a mix of established global players and emerging regional companies. Key players in this market are continuously innovating to develop advanced devices and expand their market reach.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the Hematocrit Test Devices Market include Sysmex Corporation, Abbott Laboratories, Hoffmann-La Roche Ltd., Siemens AG, Beckman Coulter, Nihon Kohden Corporation, Boule Diagnostics AB, EKF Diagnostics, Nova Biomedical, HORIBA, Ltd.

Latest Developments

In March 2024, Siemens Healthineers announced the launch of its next-generation automated hematology analyzer, with integrated hematocrit testing capabilities that promise 30% faster findings.

In April 2020, Nova Biomedical announced the launch of the State EMS Basic blood testing system for ambulance and emergency care in CE mark countries.

Hematocrit Test Devices Market, By Category

• Product:
• Hematocrit Test Meter
• Hematocrit Test Analyzer
• Application:
• Anemia
• Leukemia
• Lymphoma
• Congenital Heart Diseases
• End-User:
• Hospitals & clinics
• Diagnostic Centers
• Specialty Clinics
• Home Healthcare
• Geography:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL HEMATOCRIT TEST DEVICES MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL HEMATOCRIT TEST DEVICES MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL HEMATOCRIT TEST DEVICES MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Hematocrit Test Meter
• 5.3 Hematocrit Test Analyzer
• 5.4 Reagents and Consumables

6 GLOBAL HEMATOCRIT TEST DEVICES MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Anemia
• 6.3 Polycythemia Vera
• 6.4 Congenital Heart Diseases
• 6.5 Others

7 GLOBAL HEMATOCRIT TEST DEVICES MARKET, BY END-USER

• 7.1 Overview
• 7.2 Hospitals & clinics
• 7.3 Diagnostic Centers
• 7.4 Others

8 GLOBAL HEMATOCRIT TEST DEVICES MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL HEMATOCRIT TEST DEVICES MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Sysmex Corporation
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Abbott Laboratories
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 F. Hoffmann-La Roche Ltd.
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Siemens AG
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Beckman Coulter
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Nihon Kohden Corporation
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Boule Diagnosis AB
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 EKF Diagnostics
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Nova Biomedical
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 HORIBA Ltd.
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Research